Related Experiment Video
Updated: Dec 28, 2025

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
Published on: June 9, 2022
Glecaprevir/pibrentasvir+sofosbuvir: an optimal retreatment strategy in the setting of HCV NS5A resistance
Arshia Alimohammadi1,2, Brian Conway3, Leo Yamamoto3
1Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada aarshia@alumni.ubc.ca.
Abstract:
Some individuals do not achieve a cure of their hepatitis C virus (HCV) infection due to non-adherence or resistance associated substitutions. Salvage options that are optimised for resistance profiles are essential. We report a 56-year-old Caucasian man with fatigue, depression and confusion in the setting of untreated HCV genotype 3a infection. He received ruzasvir and uprifosbuvir for 12 weeks within a clinical trial. The patient relapsed 4 weeks after the end of treatment and at this time resistance testing showed multiple resistances including a NS5A Y93H mutation. Given that this mutation confers resistance to first line salvage options, sofosbuvir and glecaprevir/pibrentasvir was used for 12 weeks and the patient was cured of HCV infection 12 weeks after the end of treatment. This shows that sofosbuvir and glecaprevir/pibrentasvir is a viable, effective option for second line/salvage therapy of HCV infection in the setting of resistance to NS5A inhibitors with the Y93H mutation.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Subviral Agents
Treatment Resistant Cancers
Viruses with RNA Genomes
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

